Uncategorized
Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset
Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.